Digest Réseau Comment ça marche
Réseau
/
Sociétés
Da
Non vérifié

Daiichi Sankyo

Ce que nous écrivons

IndustrieIndustrie pharmaceutiqueMédecine - DiversOncologieSanté

74 communiqués de presse

Voir tous les communiqués de presse
09/12/2025
Industrie
Biotechnologie
Santé
Industrie pharmaceutique
Oncologie
Science
Vitrines/Shopping
Médecine - Divers
DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer
Source
Daiichi Sankyo
Émetteur
Business Wire
1.00
0
08/12/2025
Biotechnologie
Industrie pharmaceutique
Santé
Industrie
Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS
Source
Daiichi Sankyo
Émetteur
Business Wire
1.00
0
03/12/2025
Lois/Droit
Oncologie
Santé
Santé Publique
Industrie pharmaceutique
Cardiologie
Biotechnologie
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen
Source
Daiichi Sankyo
Émetteur
Business Wire
1.00
0
10/11/2025
Science
Biotechnologie
Industrie pharmaceutique
Oncologie
Santé Publique
Santé
Médecine - Divers
Industrie
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
Source
Daiichi Sankyo
Émetteur
Business Wire
1.00
0
31/10/2025
Science
Biotechnologie
Industrie pharmaceutique
Oncologie
Santé
Médecine - Divers
Industrie
DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer
Source
Daiichi Sankyo
Émetteur
Business Wire
1.00
0
19/10/2025
Événements
Expos
Industrie
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial
Source
Daiichi Sankyo
Émetteur
Business Wire
1.00
0
19/10/2025
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Événements
Industrie
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
Source
Daiichi Sankyo
Émetteur
Business Wire
1.00
0
19/10/2025
Événements
Industrie
Science
Hygiène alimentaire
Médecine - Divers
Biotechnologie
Santé
Industrie pharmaceutique
Santé Publique
Oncologie
DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
Source
Daiichi Sankyo
Émetteur
Business Wire
1.00
0
18/10/2025
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
Événements
Industrie
ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
Source
Daiichi Sankyo
Émetteur
Business Wire
1.00
0
18/10/2025
Oncologie
Santé
Hygiène alimentaire
Santé Publique
Médecine - Divers
Industrie pharmaceutique
Biotechnologie
Événements
Industrie
ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial
Source
Daiichi Sankyo
Émetteur
Business Wire
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0